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Abstract: During the last decade inorganic luminescent nanoparticles that emit visible 
light under near infrared (NIR) excitation (in the biological window) have played a 
relevant role for high resolution imaging of cancer. Indeed, semiconductor quantum dots 
(QDs) and metal nanoparticles, mostly gold nanorods (GNRs), are already commercially 
available for this purpose. In this work we review the role which is being played by a 
relatively new class of nanoparticles, based on lanthanide ion doped nanocrystals, to target 
and image cancer cells using upconversion fluorescence microscopy. These nanoparticles 
are insulating nanocrystals that are usually doped with small percentages of two different 
rare earth (lanthanide) ions: The excited donor ions (usually Yb
3+
 ion) that absorb the NIR 
excitation and the acceptor ions (usually Er
3+
, Ho
3+
 or Tm
3+
), that are responsible for the 
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emitted visible (or also near infrared) radiation. The higher conversion efficiency of these 
nanoparticles in respect to those based on QDs and GNRs, as well as the almost 
independent excitation/emission properties from the particle size, make them particularly 
promising for fluorescence imaging. The different approaches of these novel nanoparticles 
devoted to ―in vitro‖ and ―in vivo‖ cancer imaging, selective targeting and treatment are 
examined in this review. 
Keywords: cancer; fluorescence imaging; lanthanide-doped nanocrystals; upconversion; 
targeting 
 
1. Introduction 
Cancer is one of the leading causes of mortality in the World. Each year more than ten million 
people are diagnosed with this disease. While cancer cells are localized in a tissue, they can spread to 
distant sites within the body through a process known as metastasis. This has been one of the major 
challenges and has created numerous hurdles in finding a cure for cancer. Common cancer treatments 
include chemotherapy, radiation, therapy and surgery; however, these therapies are far from ideal and 
may not necessarily rid the patient of the cancer. In current cancer chemotherapies, nonspecific 
systemic distribution of antitumor agents through passive targeting, inadequate drug concentrations 
reaching the tumour site, as well as intolerable cytotoxicity, limit the therapeutic response and results 
in the eventual development of drug (or multiple drugs) resistance, which is a major problem when 
treating the cancer [1–3]. Radiation and surgery are more localized but may not be suitable in cases 
where the cancer has metastasized throughout the body. 
Hence there exists a need to develop novel approaches for early cancer detection and effective 
therapy, and thus contributing significantly to improving patient survival and care. In this respect, 
different variants are continuously being developed including several ligand-targeted therapeutic 
strategies (such as immunotoxins, radio-immunotherapeutics and drug immunoconjugates) to bring 
forth improvements on conventional chemotherapeutic drugs and photodynamic therapy (PDT), which 
demonstrate variable results [2,4]. 
Nanotechnology has currently emerged as a new field of multidisciplinary research, implicating 
disciplines such as biology, chemistry, physics, engineering and medicine. Medical applications of 
nanotechnology have given place to a new science, presently known as nanomedicine. This new era in 
medicine has become very promising with a large potential in personalized oncology (cancer detection, 
diagnosis and therapy) [5]. 
Ever since scientists first pondered the idea of a nano-sized particle, nanoscience and 
nanotechnology have attracted a significant interest with the promise to revolutionize technologies, be 
it through innovation and invention, or through the modification and improvement of existing ones. In 
fact, new advances in nanoscience are being realized on a daily basis, and nanoparticles have already 
found integration in various industries such as textiles, automotive and glass to name a few, and even 
as potentially novel means for environmental clean-up to capture heavy metals, which are detrimental 
to ecosystems [5–9]. 
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While nanoparticles have been and will undoubtedly be integrated in a multitude of future 
applications and technologies, of pertinent interest for this review, are the luminescent nanoparticles. 
This stems from their potential to be used as nanoprobes, capable of performing a multitude of tasks 
ranging from imaging to collection of diagnostic information and delivery of therapeutic agents (vide 
infra). Several types of luminescent nanoparticles have been the subject of meticulous investigation in 
the literature. In fact one such class of luminescent nanoparticles are quantum dots (QDs) [10–18]. 
Quantum dots represent the most extensively-studied luminescent nanoparticles, where a significant 
focus has recently been aimed towards biological applications and potential integration in imaging and 
diagnostics. The use of QDs does however raise numerous challenges associated with the safety and 
underlying toxicity especially for those QDs prepared using heavy metal elements such as CdSe, or 
CdTe [19]. In addition, imaging techniques using QDs usually rely on the use of ultraviolet (UV) light 
to excite the fluorescent label resulting in autofluorescence whereby both the analyte and the 
surrounding environment are excited showing multiple emissions and hence limited detection 
sensitivity. Moreover, research has shown that exposure to UV light can have adverse effects on 
cellular functions [20–22]. This effect is not observed using near-infrared (NIR) excitation light, which 
also offers a greater penetration depth in tissue systems relative to its UV counterpart [23]. This is due 
to the lower degree of scattering encountered when using NIR light, as scattering is dependent on the 
inverse of the excitation wavelength  raised to the power of 4 (1/4) (Rayleigh scattering). This can 
allow for imaging, diagnostics and therapeutics far into the subcutaneous regions of the body. It is in 
this regard that there has been an ever increasing interest in another class of luminescent nanoparticles 
namely lanthanide (Ln
3+
)-doped nanoparticles, which have the ability to undergo a process known as 
upconversion. These nanoparticles allow for the conversion of low energy light such as NIR to high 
energy UV or visible light (blue, green, red for example) [24]. Unlike other materials such as gold 
nanorods or QDs, which can be excited using two-photon absorption (TPA), excitation in these 
upconverting Ln
3+
-doped nanoparticles (UCNP) does not occur via ―virtual‖ excited states; it in fact 
occurs through excitation of the Ln
3+
 ions via ―real‖ electronic states of defined (relatively long) 
lifetimes. Hence, high power, ultrafast, expensive laser setups are not required for efficient excitation 
but can be achieved using low-powered readily available solid-state laser diodes. The potential for 
excitation using NIR offers several advantages, as previously discussed, especially for imaging  
(in vitro and in vivo) and biomedical applications giving a distinct advantage over conventional 
fluorescent labels. 
The interest in Ln
3+
-doped UCNPs even stems from beyond the potential to use them as 
luminescent biolabels. In fact, significant efforts are currently being undertaken to investigate the 
potential of using them as multi-modal systems capable of carrying out a multitude of tasks namely the 
harvesting of valuable diagnostic information, imaging, as well as delivery and therapeutics. In 
essence, these UCNPs are being envisaged as multimodal nanovectors, which through relatively 
simple surface modifications, can be functionalized to target specific analytes and receptor/cellular 
sites in biological systems.  
A significant focus in UCNP research has recently been directed towards cancer with an emphasis 
on developing nanoparticle conjugates, which can precisely image location of malignant cells by 
specifically seeking out tumor tissues. More importantly, current research has targeted an early 
diagnosis paradigm where cancerous tissue can be identified relatively early to allow for early 
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intervention and improve the chances for successful treatment and patient survival rate. Nanoparticle 
surfaces can be readily manipulated in order to conjugate chemical entities. In that sense, specific and 
active targeting of overexpressed receptors (folates for example) on cancer cells can be achieved by 
functionalizing the appropriate molecule to the UCNP surface. Surface functionalization is not limited 
to one type of molecule, meaning molecules bearing various functional groups can be conjugated to 
the UCNP surface using well established bioconjugate chemistry techniques. It follows that UCNPs 
have become an interesting tool and offer a novel means to approach a treatment to a serious and  
life-threatening disease such as cancer. 
This review aims to summarize the progress achieved to date regarding the use of luminescent 
UCNPs for in vitro and in vivo imaging of cancer cells. 
2. Fluorescence Properties 
In a typical case, when a medium fluoresces as a consequence of excitation with a source of light, 
the wavelength of the fluorescence emission is usually longer than that of the excitation source. 
However, under certain circumstances, light may be emitted with wavelengths shorter than those of the 
light generating the excitation. These processes are possible via excitation mechanisms, which involve 
more than one absorbed photon per single emitted photon and are known as upconversion. The 
simplest example of an upconversion process is illustrated in Figure 1a, and takes place via sequential 
absorption of pump photons. In this multistep mechanism, a first absorption process  excites an ion 
in the ground state to some metastable excited level (that can be a real or a virtual level). In the second 
step, further absorption may take place raising the ion to a higher excited state . Finally, the ion 
relaxes back to the ground state  with the emission of a photon of light equivalent to the energy gap 
between the excited and the ground states. 
Figure 1. Principal mechanisms for upconversion (a) excited state absorption, (b) energy-transfer. 
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Lanthanide ions are among the most efficient systems capable of producing upconversion 
luminescence; hence emission in the visible can be achieved following excitation in the near-infrared 
(NIR) regime [24,25]. Although upconversion emission can be theoretically expected from most 
lanthanide ions, visible optical emissions under low pump power intensities (ca. 10 W/cm
2
) are only 
generated by ions, which possess equally spaced energy levels facilitating photon absorption and 
energy transfer steps involved in upconversion processes. Tripositive erbium (Er
3+
), thulium (Tm
3+
), 
and holmium (Ho
3+) are examples of ions possessing these ―ladder-like‖ levels and are typically 
selected as ―activator‖ (or acceptor) ions for the majority of UCNP systems [24,26–33]. 
To enhance upconversion efficiency, tripositive ytterbium (Yb
3+
) is frequently used as a ―sensitizer‖ 
(or donor) in combination with the activator ion. The Yb
3+
 absorption band, located at circa 980 nm, 
has a larger absorption cross-section relative to that of the other lanthanide ions (Er
3+
, Tm
3+
 or Ho
3+
) 
and its emission band matches well with many emissions of typical upconverting lanthanide ions 
(Ln
3+
) thereby facilitating efficient energy transfer from the Yb
3+
 ion to other Ln
3+
 ions. A basic 
scheme of the absorption and emission processes in a typical upconverting nanoparticle comprised of 
sensitizer and activator ions is presented in Figure 1b. The sensitizer ion (typically Yb
3+
) is raised to an 
intermediate excited state via an incoming pump photon . A non-radiative energy transfer to a 
neighbouring activator ion will raise the activator to a resonant intermediate excited state . A second 
non-radiative energy transfer may occur further raising the activator ion to a higher excited state . 
This is followed by visible emission of the activator ion while the sensitizer Yb
3+
 ion returns to the 
ground state . Hence, the sensitizer and the activator interact to excite the activator to the higher 
energy level from which the visible emission takes place. The efficiency of this process is highly 
dependent on the structure and symmetry of the host crystal. Materials with low-energy phonon 
vibrations have been shown to be among the strongest emitters. The importance of the symmetry has 
been demonstrated in the fact that the hexagonal phase of NaYF4:Er
3+
, Yb
3+
 (or NaGdF4:Er
3+
, Yb
3+
) 
crystals possess a higher efficiency relative to their cubic counterparts [34]. Numerous and different 
emission colors may be obtained by the variation of the type and concentration of the sensitizers and 
activators [26,35]. 
The non-linear nature of the excitation process of upconversion makes possible for the use of 
UCNPs as luminescent markers for upconversion imaging [36]. Traditional two-photon excited 
imaging relies on the use of high-power NIR lasers focused to a spot size in which an efficient  
two-photon excitation of the fluorophore can occur. As the excitation probability of the fluorophores 
shows a quadratic dependence on the incident pump power, the excited sample volume is restricted to 
the focal volume of the beam, so that the spatial resolution may be improved (Figure 2) [37]. 
Collection efficiency is also higher than that in other high-resolution microscopy techniques as  
two-photon excitation fluorescence microscopy is based on limiting the excited volume instead of 
limiting the observation area. As the excitation is achieved using NIR luminescence, two-photon 
excited imaging is particularly suitable for studying deep tissue systems. In addition to the higher 
penetration depth in tissues, the NIR radiation is less phototoxic relative to UV radiation traditionally 
used in bioimaging experiments. On the other hand, the localization of the two-photon excitation 
volume to the focal plane further minimizes the volume in which tissue damage may occur to a  
sub-femtolitre volume. Both aspects result in a dramatic increase in viability of biological specimens. 
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Figure 2. Schematic explanation of the increment of the spatial resolution achieved by 
using (A) two-photon upconversion processes when compared to (B) a single photon 
absorption process. The energy level represented by the solid line may represent either a 
real or a virtual intermediate state (such as in the case for quantum dots). 
 
Organic fluorophores that have been traditionally used for luminescent bioimaging present several 
drawbacks; for instance, they have broad emission spectra unsuitable for multiplex biolabeling, require 
UV light for proper excitation, and often suffer from photodegradation on exposure to external 
illumination. These drawbacks can be mediated by using inorganic nanoparticles such as QDs, gold 
nanorods (GNRs) and UCNPs. In particular, high-resolution optical images have been obtained by 
using quantum dots nanoparticles (QDs), and gold nanorods (GNRs). Both types of nanoparticles 
(QDs and GNRs) share the capability of converting NIR light to visible with the UCNPs; however, 
they do suffer from numerous drawbacks. In the case of QDs, UV is typically the principal source of 
excitation, which is less advantageous in comparison to NIR. Furthermore, the use of QDs for 
biological detection is limited by several factors, mainly their potential toxicity, as they include in their 
components heavy metals (e.g., Cd) [38,39]. Several non-toxic based QDs based on ZnS have been 
proven for biological imagining, however, they still present the limitation of UV excitation [40–43]. 
Intermittent emission (blinking) also limits their use for labeling individual biological molecules [38]. 
The use of GNRs may be attractive in therapeutic applications [44]; however, it can cause damage to 
the biological specimens due to localized heating of the GNRs, which result from the plasmon 
resonance with the pump beam. 
Upconverting nanoparticles present an interesting alternative to QDs and GNRs. To date, no 
significant toxic effects have been reported in cellular studies using UCNPs [45–49]. In fact little to no 
toxicity has been reported in in vivo studies using the mouse model. As the nanoparticles typically 
contain a large number of Ln
3+
 dopant ions, they do not blink under continuous irradiation of a NIR 
laser [50,51], which is contrary to what has been observed for QDs. Upconversion occurs within the 
(A) 
(B) 
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host crystal; it is therefore less affected by the chemical and biological environments in comparison to 
the emission of QDs and GNRs. Furthermore, no heating effects have been observed due to the use of 
UCNPs in imaging experiments of cancer cells [52]. 
The principal advantage of UCNPs is that they present higher NIR-to-visible conversion efficiency 
relative to both QDs and GNRs as can be seen in Figure 3 [53] as their emission is based on physically 
existing states. The probability of two-photon absorption is proportional to the square of the incident 
laser intensity, so in general the use of very intense laser pulses is necessary (in general ultra-short 
pico- or femto-second pulsed lasers, so the average power is low and thermal damage to the sample 
can be minimized). The superior efficiency of UCNPs makes possible of the use of low intensities  
(1–103 W/cm2) and so inexpensive continuous wave lasers for imaging processes, instead of the  
high-intensities (10
6–109 W/cm2) associated to ultra-fast pulsed laser sources for the generation of a 
simultaneous two-photon excitation process. Hence, this reduces the elevated powers needed at the 
focal volume where photochemical interactions occur, and minimizes the damage brought about to 
biological samples. Upconverting nanoparticles have the important advantage of being photoexcitable 
in the near infrared (NIR) (most often at around 980 nm) in the region known as the biological optical 
window. In this region the auto-absorption of any biological matter is quite weak (with the exception 
of water where absorption is moderately weak) thereby reducing, to virtually zero, any background 
absorption and autofluorescence. In addition, commercially available diode laser systems are well 
matched to the absorption of Yb
3+
 at 980 nm, providing an ideal and inexpensive excitation source  
for UCNPs. 
Figure 3. Left Side. (A) Multiphoton relative luminescence signal generated by the QD, 
GNR, and UCNP solution as obtained under fs laser excitation at 800, 830 and 980 nm, 
respectively. Pump intensity was 1 MW/cm
2
; (B) Multiphoton relative luminescence signal 
generated by the QD, GNR, and UCNP solution as obtained under cw laser excitation at 
800, 830 and 980 nm, respectively. Pump intensity was 1 MW/cm
2
. Right Side: Photos 
corresponding to the naked eye observations of the fluorescent samples. The pump 
intensity was kept the same in both cases (CW and 100 fs excitation) ([53], reproduced by 
permission of The Optical Society of America). 
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From the image analysis perspective, UCNPs present multiple advantages relative to other 
fluorophores. Firstly, the emission bands of the lanthanide ions are quite narrow thus enabling their 
easy separation, leading to increased selectivity of the imaging assay. Secondly, different Ln
3+
 ions or 
combination of Ln
3+
 ions will emit at different visible wavelengths upon excitation with 980 nm, 
suggesting that multiple analytes can be detected simultaneously by simply changing the dopant ion(s) 
in the UCNP. Thirdly, the long fluorescent lifetimes of most Ln
3+
-doped materials (μs to ms range) 
renders them highly suitable for time-gated detection applications since any inherent fluorescence from 
biological systems, for example proteins, with natural fluorescence is in the 1–10 ns range, can be 
eliminated. Finally, the wavelengths of the Ln
3+
-doped UCNP fluorescence is not particle-size dependent 
and each Ln
3+
 dopant ion possesses unique emission lines thus allowing for multiplexing capabilities. 
3. Synthesis, Surface Modification and Bioconjugation  
In recent years, several research groups have prepared UCNPs, using various synthetic  
techniques, capable of producing intense luminescence in the UV to visible regions following NIR  
excitation [49,54–56]. Among the various types of UCNPs, NaYF4 (and the isostructural NaGdF4) is 
known to be one of the most efficient UCNP hosts due to its intrinsically low lattice phonon  
energies [33,57]. The crystal structure of NaYF4 manifests itself in two forms, namely the cubic () 
and hexagonal (β) phases. The hexagonal β-phase of NaYF4 has three cation sites, the first 
accommodating yttrium ions and the second accommodating both yttrium and sodium ions with C3 
symmetry. The third site accommodates sodium ions and possesses Cs symmetry. Previous 
investigations have shown that the luminescence intensity signal of hexagonal β-NaYF4 is at least one 
order of magnitude greater than that of the cubic -NaYF4 [34]. NaYF4/NaGdF4 co-doped with 
trivalent rare earth ions (Ln
3+
) have been the subject of many investigations for use in biological 
applications. Such applications include fluorescence resonance energy transfer (FRET) assays, DNA 
detection, diagnostics, targeting, drug delivery, in vivo/in vitro cancer targeting and imaging as well as 
photodynamic therapy [49,51–53,58–76]. Additionally, as a potential multimodal imaging probe, 
NaGdF4 has been evaluated for use in both simultaneous fluorescence and magnetic resonance imaging 
(MRI) [51]. We present an overall review of the most prominent synthetic approaches to prepare highly 
luminescent and water-dispersible UCNPs (through direct synthesis or surface modification). 
Furthermore, strategies for surface chemical modifications useful for the introduction and conjugation 
of biomolecules at the surface of the UCNPs necessary for targeting and delivery are also discussed. 
The hydro/solvothermal method is one common approach to prepare fluoride-based UCNPs.  
For this synthesis, NaCl, NH4F and lanthanide chlorides are used as the precursors to the UCNP 
formation [77]. This method uses a pressurized autoclave and relatively low reaction temperature 
conditions in comparison to the thermal decomposition technique (vide infra) [78]. The shape, the 
crystalline phase and the size of the nanoparticles are controlled using hydrophobic organic ligands 
such as oleic acid [79]. The hydrothermal synthesis is an effective and convenient method for the 
preparation of the pure hexagonal (β) phase of NaYF4 with controllable morphologies and architectures 
including plates, spheres and ellipses by varying the oleic acid surfactant concentration [77]. In the same 
approach, hexagonal-phase β-NaYF4:Yb
3+
, Er
3+
 UCNPs stabilised with cetyltrimethylammonuim 
bromide (CTAB) with controllable size and morphology were produced by Li et al. [33]. Many studies 
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have reported that hydrophilic molecules such as polystyrene [80], ethylenediamine tetraacetic acid 
(EDTA) [81] or an amphiphilic surfactant such as poly(vinylpyrrolidone) (PVP) [82] may be used as 
chelating agents to enhance the stability, aqueous dispersibility and potential for functionalization of 
the fluoride-based UCNPs. 
Polyol synthetic routes may also be used to prepare UCNPs. In fact, aqueously dispersible cubic () 
NaYF4:Yb
3+
, Er
3+
 and NaYF4:Yb
3+
, Tm
3+
 UCNPs, with a mean particle size of 17–30 nm showing 
multi-color upconversion emission for multiple labeling in biological detection, were obtained using 
polyol capping ligands [83]. The cubic-to-hexagonal phase transition may be carried out during the 
solvothermal process and results in an enhanced fluorescence intensities of the UCNP emissions. From 
one-step hydrothermal methods, water-dispersible polyethylenimine (PEI)-capped NaYF4:Yb
3+
, Er
3+
 or 
Tm
3+
 UCNPs were synthesized [60]. PEI offers several advantages as a capping ligand principally due 
to its low toxicity profile and potential for further functionalization due to the terminal NH2 groups. 
Zhang et al. demonstrated that PEI-capped UCNPs showed little toxicity especially to HT-29 colon 
cells following MTT assays, which showed a high cell survival rate. The surface of the PEI-capped 
NaYF4:Yb
3+
, Er
3+
 UCNPs synthesized using the hydrothermal method were subsequently conjugated 
with folic acid following a reaction between the carboxyl groups of folic acid and the amino groups of 
the PEI-capped UCNPs [60]. 
A novel two-phase solvothermal approach was used for the synthesis of hydrophilic  
β-NaYF4:Yb
3+
/Er
3+
/Tm
3+
/Ho
3+
 with an average particle size of approximately 25 nm using lanthanide 
stearates as precursors [26]. The same group also reported the synthesis of water dispersible 
spherically-shaped NaYF4:Yb
3+
, Er
3+
 UCNPs stabilized with polyacrylic acid (PAA), polyvinylpyrrolidone 
(PVP), or polyethylene glycol (PEG) with a particle size distribution ranging from 25 to 45 nm using a 
one-step hydrothermal synthesis [84]. Recently, a user-friendly method previously developed by Li [85] 
(Figure 4) was used to synthesize NaYF4:Yb
3+
, Er
3+
/NaGdF4 core/shell UCNPs [86] coated with silica 
for in vivo optical and magnetic resonance imaging applications. In a modified hydrothermal 
microemulsion strategy, 6-aminohexanoic acid was used for the preparation of amine-functionalized 
UCNPs [65]. These UCNPs were conjugated via an amide linkage through folic acid-NHS conjugates. 
Figure 4. TEM images of NaYF4:Yb
3+
, Er
3+
 nanospheres (A), nanoellipses (B), nanoplates (C, D) 
obtained by solvothermal methods ([85], reproduced by permission of the Institute of Physics). 
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The thermal decomposition synthesis presents several advantages over other preparation methods, 
namely the strict control over the synthetic parameters and the formation of highly monodisperse and 
luminescent UCNPs [27,78,87–90]. In this method, the lanthanide oxides are first transformed to the 
trifluoroacetate form and the resulting precursors of the lanthanide organic acid salts are then 
decomposed, in the presence of a capping ligand (such as oleic acid) to produce hydrophobic UCNPs. 
Controlling the ratio of the precursors to the capping ligands, as well as the reaction temperature and 
time allows for a tailored synthesis of UCNPs with a variety of morphologies, sizes and phases. Using 
this method Capobianco’s group synthesized cubic phase NaYF4 UCNPs co-doped with the Er
3+
/Yb
3+
 
or Tm
3+
/Yb
3+
 and hexagonal phase NaGdF4:Ho
3+
/Yb
3+
 with a particle size ranging from 15 to  
27 nm [27,28,87,91] (Figure 5). In addition, diamond-shaped LiYF4:Tm
3+
/Yb
3+
 UCNPs were obtained 
using the same synthetic route. Capobianco’s group also reported on the synthesis of core/shell UCNPs 
and found that following shell formation, significant upconversion luminescence enhancement  
was observed. This was observed for the core/shell UCNPs comprised of NaGdF4:Ce
3+
, Tb
3+
  
(core)/NaYF4 [92] and NaGdF4:Er
3+
, Yb
3+
 (core)/NaGdF4:Yb
3+
 [93]. Other groups have also reported 
on the synthesis of core/shell systems such as NaYF4:Yb
3+
, Er
3+
 (core)/NaGdF4 [86], which may 
provide a great potential as magnetic and upconverting fluorescent bimodal cancer probes. In this 
context, Ryu et al. recently reported on the synthesis of hexagonal phase NaGdF4:Yb
3+
, Er
3+
 (or Tm
3+
)  
UCNPs ranging in size from 10–40 nm in size, which show efficient upconversion and magnetic 
properties [94]. 
Figure 5. (A, B) Low-resolution TEM images of NaYF4: Yb
3+
, Er
3+
 sample showing 
uniformity of the particles [27] and (C) TEM image of oleic acid-capped NaGdF4:Yb
3+
 
/Ho
3+
 obtained from thermal decomposition ([91], reproduced by permission of The 
American Chemical Society). 
 
Another thermal decomposition approach relies on the use of a microemulsion method. In this 
synthesis, the trifluoroacetate precursors (typically used in thermal decomposition) are replaced with 
NaF and rare earth oleates as precursors [95]. This approach is simple and requires no injection 
processes (used for the addition of the precursors to the reaction vessel). During the reaction no 
additional capping-reagents or surfactants are required to maintain size control as the sizes may be 
simply tuned by adjusting the concentration of NaF. Using this approach, oleate-capped  
β-NaYF4:Yb
3+
, Er
3+
 (or Tm
3+
) UCNPs showing high monodispersibility and particle sizes ranging 
from 18–45 nm have been synthesized (Figure 6). In the same procedure the up-conversion 
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luminescence was enhanced by using a core/shell structure comprised of NaYF4:Yb
3+
, Er
3+
/NaYF4 
(undoped). Moreover monodisperse, well-crystallized and multi-colored-emission oleate-capped 
NaGdF4:Ce
3+
(Yb
3+
), Ln
3+
 (Ln
3+
 = Tb
3+
, Eu
3+
, Dy
3+
, Sm
3+
, Er
3+
 or Tm
3+
) comprised of uniform short 
nanorods were also obtained [96]. 
Figure 6. (i–viii) TEM images taken with different magnifications of: (A) β-NaYF4:Yb
3+
, 
Er
3+
 (Tm
3+
) [95] and (B) β-NaGdF4:Ce
3+
 (Yb
3+
) Ln nanorods (Ln:Tb, Eu, Dy, Sm, Er or 
Tm) UCNPs [96] synthesized by microemulsion in a thermo decomposition methods from 
rare earth oleate as precursors (Reproduced by permission of The Royal Society of Chemistry). 
 
The thermal decomposition method is an excellent synthetic procedure to prepare UCNPs; however, 
the main disadvantage lies in the fact that it requires high reaction temperatures (310–330 °C) and 
high-boiling organic solvents such as octadecene. Furthermore, while the UCNPs prepared via thermal 
decomposition have well defined morphologies and sizes, they are hydrophobic and require further 
modification for aqueous dispersibility. These hydrophobic UCNPs may be transformed into  
water-dispersible UCNPs via a ligand-exchange pathway with various hydrophilic polymers or through 
silica coating. 
3.1. Strategies for Water Dispersibility 
Different synthetic approaches with special emphasis on applications in biolabeling, targeting and 
imaging are discussed below and concern themselves with processes which allow for the transfer of 
hydrophobic nanoparticles to a hydrophilic medium. 
To render hydrophobic oleate-capped nanoparticles water dispersible, one approach involves 
oxidation of the carbon-carbon double bond of the oleate ligand. The oxidation of the carbon-carbon 
double bonds of the oleate ligand, using the Lemieux-von Rudloff reagent [97], results in the formation 
of azelaic acid (C9), which renders the hydrophobic oleic acid-capped UCNPs, obtained by thermal 
decomposition methods, water dispersible. The carboxyl groups (-COOH) obtained at the surface of 
UCNPs may be further conjugated to biomolecules. Recently, a novel approach [98] was developed to 
obtain water-dispersible ligand-free upconverting lanthanide-doped NaYF4:Er
3+
,Yb
3+
 nanoparticles 
with high upconversion luminescence intensities in aqueous solutions. This approach was based on 
(A) 
(B) 
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removing the oleate ligand from the surface of oleate-capped upconverting nanoparticles synthesized 
via thermal decomposition using a simple acid treatment process. It was shown that after removing the 
oleate, the surface charge of the Ln-UCNPs can be tuned through pH control where intense red 
emission was obtained at neutral pH using this strategy. These ligand-free upconverting nanoparticles 
were further functionalized with heparin and basic fibroblast growth factor (bFGF) molecules [99]. 
The heparin conferred stability and protected bFGFs from inactivation. The presence of bFGF at the 
surface of the nanoparticles assured affinity with the fibroblast growth factor receptors at the cell 
membrane. These heparin-bFGF functionalized nanoparticles showed biocompatibility with mammalian 
cells and were successfully used in upconversion fluorescence to imagine the HeLa epithelial cancer cells. 
Alternative approaches to achieve water dispersibility for hydrophobic UCNPs include ligand 
exchange reactions using a number of different ligands such as poly(ethylene glycol) (PEG) [100,101], 
PEG-diacid [102], PEG-phosphate [103], sodium citrate [104], hexanedioic acid (HDA) [105], 
polyacrylic acid (PAA) [91,106,107] or polyvinylpyrrolidone (PVP) [106] (Figure 7). 
Figure 7. TEM images of oleic acid-UCNPs dispersed in (A) cyclohexane and (B) citrate 
coated-UCNPs dispersed in water—Inset: HRTEM image of single nanoparticle ([104], 
reproduced by permission of Elsevier) and (ii) TEM images of NaYF4:Yb
3+
, Er
3+
 
(C) oleate-stabilized, (D) ligand-exchanged with PVP ([108], reproduced by permission of 
the Royal Society of Chemistry). 
 
Other approaches rely on the use of hydrophobic van der Waals interactions, electrostatic layer-by-
layer assembly or surface polymerisation for encapsulation of hydrophobic UCNPs with amphiphilic 
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polymers or silanes (Figure 8) to obtain water-dispersible UCNPs [54]. These encapsulated-UCNPs 
possess functional groups, which allow for further biological modifications. For example, the 
hydrophobic hexagonal phase of NaYF4:Yb
3+
, Er
3+
 (Tm
3+
) core and NaYF4:Yb
3+
, Er
3+
 (Tm
3+
)/NaYF4 
NP core/shell systems can be rendered hydrophilic using a layer of amphiphilic poly(acrylic acid) 
(PAA) polymer as reported in the work of Yi et al. [109]. In another example, the hydrophobic UCNPs 
synthesized via thermal decomposition were rendered water dispersible following labeling with 
octylamine modified poly(acrylic acid) polymer conjugated, using EDAC, with an amino-functionalized 
poly(ethylene glycol) PEG (OA-PAA-PEG) molecule [110]. The polyethylene glycol (PEG) groups 
present on the surface of UCNPs confer aqueous dispersibility and biocompatibility. In a recent work, 
the PEG amphiphilic polymer was also used to render the hydrophobic NaYF4:Yb
3+
, Er
3+
 UCNPs 
water dispersible [63]. These PEGylated UCNPs were labeled with folic acid (FA) by conjugating the 
amine-functionalized PEG-NH2 with activated folic acid. The FA-PEG-UCNPs were further loaded 
with a chemotherapy drug molecule, doxorubicin (DOX), by simple physical adsorption via a 
supramolecular chemistry approach. 
Figure 8. TEM images of LiYF4:Yb
3+
, Tm
3+
 nanocrystals ([28]) (A) before and (B) after 
silica coating as well as TEM images of NaYF4:Yb/Er up-conversion nanocrystals: (C, D) 
before and (E, F) after silica coating ([75], reproduced by permission of Wiley). 
 
3.2. Surface Modification and Functionalization for Biological Applications 
As shown above, a multitude of approaches have been employed for the preparation of UCNPs 
amenable to functionalization for biological applications. For such applications, it is highly desirable to 
prepare UCNPs, which are dispersible in bio-relevant media, with a surface that can be appropriately 
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functionalized with targeting molecules such as, antibodies, peptides, cancer specific receptor-recognition 
molecules, drugs, etc. [111]. Numerous investigations have shown that modification of the UCNP 
surface with hydrophilic molecules allows for the introduction of reactive groups such as amino (NH2) 
or carboxylic (COOH) groups and may improve stability as well as the dispersibility of the particles in 
biological media. These groups allow for covalent binding with specific diagnostic and therapeutic 
(bio)molecules, fluorophores as well as targeting moieties as previously mentioned. Covalent binding 
is preferred in biological applications so as to avoid ligand desorption from the nanoparticle surface. 
The most important chemical modification approaches using amine-terminated UCNPs for covalent 
binding with biomolecules are presented in Figure 9. Biomolecules are usually pre-activated to 
introduce the appropriate chemical functionality, which allows for bond formation to occur with the 
UCNP-NH2 surface. The most common activation chemistry relies on the preparation of a  
N-hydroxysuccinimide (NHS) ester that can be formed by the reaction of a carboxylate with NHS in 
the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC). The latter mediates the 
formation of an amide linkage between a carboxylate group and an amine [112]. Other strategies for 
biolabelling are based on the strong non-covalent biological interaction between avidin/streptavidin  
(or variations thereof) and biotin Figure 10. For example, streptavidin may be covalently coupled with 
antibodies or enzymes through EDAC; the biotin-streptavidin combination has been investigated in 
many biotinylated nanoparticle systems [112]. 
Figure 9. Bioconjugation schemes for the attachment of bio(molecules) (R) presenting 
different target sites (amines, carboxyl, hydroxyl, thiols, isothiocyanate) onto the surface of 
amine-coated-UPNPs. Reagents: 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC), succinimidyl ester (NHS), succinimidyl iodo acetate (SIA),  
N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP). 
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Figure 10. Different functionalization approaches used for UCNPs in order to provide a 
targeting or therapeutic function. 
 
4. In Vitro and in Vivo Imaging 
One of the first demonstrations of UCNPs as two-photon excited fluorescent imaging probes was 
published by Chatterjee et al. [71] in 2008. In this seminal work, the authors demonstrated that 
NaYF4:Er
3+
, Yb
3+
 UCNPs coated with polyethylenimine (PEI) and conjugated with folic acid could be 
used to target human HT29 adenocarcinoma cells and human OVCAR3 ovarian carcinoma cells. 
These two cell lines were used since they are known to express abnormally high levels of folate 
receptors on their surfaces. The folic acid conjugated UCNPs were incubated for different times and 
after washing, the visible upconversion fluorescence of the UCNPs attached to the cell surface was 
easily observed following excitation with 980 nm NIR radiation (Figure 11). Moreover, it should be 
noted that luminescence from the UCNPs could be observed within an hour; however, cellular uptake 
of the nanoparticles was much slower and required approximately 24–48 h of incubation. Also of note 
from this work, the authors injected Wistar rats with the PEI-coated UCNPs at a depth of 
approximately 10 mm and visible fluorescence was clearly observed. 
Following this first report on cellular imaging using UCNPs, the potential of lanthanide-doped 
UCNPs became apparent. From 2008–2011, a stark increase in publications concerning imaging using 
UCNPs was observed in the literature. A significant number of publications placed a strong emphasis 
on the imaging capabilities at the cellular level. These works also focused on the imaging of cancer 
cells. A wide variety of cell lines was investigated encompassing breast, colon, ovarian, skin, 
pancreatic, ocular, and brain cancer cell lines (vide infra). The vast majority of these works focused on 
the synthesis of Ln
3+
-doped UCNPs, many of which required post synthetic modification to achieve 
water dispersibility, and their surface functionalization to target the cancer cells. Moreover, most of the 
works reported focused on fluoride-based UCNPs, including NaYF4, NaGdF4 and LaF3 with some 
works reporting the use of an oxide host, namely the well-studied Y2O3 [113,114] During the imaging 
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experiments, the binding/uptake of the UCNPs into the various cell lines occurred through non-specific 
means [26,31,46,47,52,64,73,75,76,103,104,115–117]. 
Figure 11. In vitro imaging using folic acid modified PEI/NaYF4 nanoparticles The top 
row shows the bright field (A), confocal (B), and superimposed images of live human 
ovarian carcinoma cells (OVCAR3) (C) and the bottom (E, F) human colonic 
adenocarcinoma cells (HT29) ([71], reproduced by permission of Elsevier). 
 
In contrast, several works investigated the use of targeting molecules as a means for specific 
binding, which can lead to efficient cellular uptake and enhanced imaging within the cell walls and 
organelles. Several targeting molecules have been reported including organics, such as folic acid,  
β-cyclodextrins and carbonized glucose (Figure 12) [63,65,71,118,119], or peptides and antibodies 
such as RGDyK, cyclic RGD and anti-Claudin 4 to name a few (Figure 13) [26,66,70,72,120]. One of 
the most important findings in these works was related to the specific uptake of the UCNPs in the cell 
in comparison to non-surface functionalized UCNPs. The difference in emission intensity following 
excitation with NIR radiation was used as a comparative marker to conclude that specific binding and 
the ensuing enhanced cellular uptake was clearly more effective when using a targeting ligand on the 
UCNP surface. Another important finding was regarding the cytotoxicity of the UCNP probes in MTT 
assays. The works reviewed generally reported that UCNPs did not result in any significant cell death 
even after 24–48 h incubation times for concentrations ranging from 25 g/mL to 500 g/mL  
(Figure 14) [31,45–47,63,65,66,76,115–119,121–123]. In contrast, nanoparticles bearing cancer drugs, 
such as doxorubicin for example, on their surface were found to greatly enhance the death of the 
cancer cells as would be expected due to the underlying effect of the therapeutic agents (Figure 15). 
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Figure 12. First row: luminescence (A), bright-field (B) and overlap of both images (C), of 
KB cells cultured with UCNPs-Ad/β-CD ([123], reproduced by permission of the Royal 
Society of Chemistry). Second and third rows: Fluorescence imaging of MB49 cells 
cultured with: carbonized glucose-coated UCNPs (D), (E) and (F); silica-coated UCNPs 
(G), (H) and (I) ([120], reproduced by permission of the Institute of Physics). 
 
Figure 13. Confocal images of Panc 1 cells treated with up-conversion NPs (A,B) and 
down-conversion NPs (C, D). (A) and (C) show non-bioconjugated nanophosphors,  
(B) and (D) show cells targeted with nanophosphors conjugated with anti-claudin 4 and 
anti-mesothelin, respectively ([124], reproduced by permission of Wiley). 
 
Cancers 2012, 4 
 
 
1084 
Figure 14. Left: Cell viability estimated by MTT proliferation tests for different incubation 
concentrations of: (A) HeLa cells incubated with Folic Acid-UCNPs [65]; (B) KB cells 
cultured in the presence of citrate capped-NPs ([125], reproduced by permission of Elsevier). 
 
Figure 15. Cell viability data of FR positive KB cells (A) and negative HeLa cells (B) 
treated with FA-UCNP-DOX and UCNP-DOX ([63], reproduced by permission of Elsevier). 
 
4.1. Animal Imaging 
The majority of papers making use of UCNPs for two-photon excited fluorescence imaging of 
cancer cells rely on the Er
3+
 emitting ion, which produces upconverted green or red emission upon 
excitation with 980 nm. However, to improve the contrast and tissue penetration capability of the 
imaging process, efforts have targeted the use of NIR-to-NIR UCNPs. In fact, Prasad’s group has 
recently shown that deep tissue imaging can be carried out up to a depth of 3.2 cm [126]. Nyk and  
co-workers [31] used NaYF4:Tm
3+
, Yb
3+
 UCNPs for NIR-to-NIR imaging following a ligand exchange 
process between the oleate-capping ligand with 3-mercaptopropionic acid. The Tm
3+
 ion has strong 
emission in the UV/blue and NIR regions. Thus, they exploited the strong NIR emission of Tm
3+
 at 
approximately 800 nm for NIR-NIR imaging, and so a deep penetration for the excitation light and for 
observing the emission signal. The authors incubated human pancreatic cancer cells, Panc 1 with 
UCNPs for 2 h and as a result of complete lack of autofluorescence, high contrast fluorescence images 
of the cancer cells were obtained. They also noted that the fluorescence imaging showed the feature of 
inherent three-dimensional localization very similar to images obtained with two-photon excited 
fluorescence, which is a function of the quasi-quadratic dependence of the emission intensity on the 
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excitation wavelength. Moreover, Nyk and co-workers demonstrated the suitability of this technique 
for in vivo imaging by injecting Balb-c mice and imaging them 2 h post-injection (Figure 16). The 
authors observed an intense NIR fluorescence centered at approximately 800 nm that was easily 
detectable through the skin without the removal of the animal’s fur. The animals showed little signs of 
short-term toxicity up to 48 h post-injection. High contrast images of the liver and spleen were 
obtained and showed saturated levels of fluorescence, which was indicative of high cellular uptake of 
the UCNPs. Again, this high contrast was the result of the difference in fluorescence intensity between 
the background (which was essentially zero) and the fluorescence signal resulting from the  
NIR-to-NIR upconversion process. 
Figure 16. Images of mouse injected in vivo with UCNPs; before (A) and after dissection (B). 
The red color indicates emission from UCNPs, green and black show background as 
indicated by the arrows and the inset ([31,125], reproduced by permission of the American 
Chemical Society). 
 
Park et al. [51] investigated the bimodal imaging potential of UCNPs by synthesizing 20–41 nm 
particles. They demonstrated that they can carry out single particle imaging and that these UCNPs can 
be used for simultaneous optical and magnetic imaging. The work carried out on SK-BR-3 cells 
showed no autofluorescence and was void of photoblinking (a problem typically associated with some 
QDs). Imaging was successful even at a concentration of 100 mg/L Gd3+. In addition, at concentrations 
of ~3.0 mM, both 20 and 41 nm UCNPs showed contrast enhancement in T1-weighted images. 
In 2010, Shi and his coworkers [125] prepared bimodal magneto/luminescent probes using the neck 
formation strategy of silica. A common byproduct of silica coating is the necking behavior of the silica 
coated particles where two or these particles are conjoined at the edges. The authors prepared 
superparamagnetic iron oxide nanoparticles (SPIONS) as well as UCNPs co-doped with Er
3+
 and Yb
3+
 
and following silica coating of the nanoparticles, they obtained silica-shielded magnetic upconversion 
fluorescent oligomers (SMUFOs). Enhancement of the contrast was observed in a 3.0T clinical MRI 
instrument, which prompted in vivo studies of the SMUFOs in SD mice bearing a Walker 256 tumor 
(Figure 17). Following subcutaneous injections, change in the spin-spin relaxation time T2 value was 
observed within 5 min and following NIR excitation of the tumor area, minimal autofluorescence was 
observed and the tumor was easily observed by the naked eye. 
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Figure 17. Top: sensitivity of in vitro MRI of SMUFO treated MCF-7 cells at different 
concentrations. Bottom: in vivo MR and upconversion fluorescence bimodal imaging of 
Walker 256 tumor using SMUFO. In vivo whole body pre-injection (A) and post-injection 
(B) MRI of mouse bearing a Walker 256 tumor. Pre-injection image (A bottom) and  
post-injection image (B bottom) of the upconversion fluorescence imaging of tumor in vivo 
using NIR laser ([115,125], reproduced by permission of Wiley). 
 
Li et al. prepared tri-doped UCNPs using a hydrothermal method. The particles were rendered 
hydrophilic via oxidation of the capping ligand (oleic acid) [31]. The authors first demonstrated that 
the particles can be internalized in the cells and do not simply stain the surface. The authors also 
proceeded to demonstrate that the gadolinium found in the host material may be used as a contrast 
agent with a similar relaxivity parameter to that reported for Gd-DTPA. Injection in Kunming mice via 
the tail vein resulted in significant contrast enhancement following a comparison of pre and post 
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injection images (Figure 18). In and ex-vivo, the authors reported that the nanoparticles were highly 
accumulated in the liver and spleen. Little to no accumulation was observed in the heart, lungs or 
kidneys. Similar work was reported by Yu et al. [45], where they conjugated the nanoparticles with 
chlorotoxin to target C6 Glioma cells. The authors also carried out in vivo studies in Balb-c mice and 
found no significant change in mice behavior after 7 days. They also found that ex vivo analysis of the 
various organs showed accumulation in the lung, spleen and liver after 7 days. Tumor targeting and 
imaging in xenograft bearing nude mice was successful and upconversion fluorescence was observed 
to emanate from the tumor area of the mouse. 
Figure 18. (Left column, A): T1-weighted and color-mapped MR images for different 
mass and molar concentrations of (top) AA-NPs and (bottom) Gd-DTPA. (Left  
column-bottom): Color-mapped (B) coronal images of the whole body and (C, D) 
transversal cross-sectional images of the liver (L) and spleen (S) of mice at pre-injection 
and at 40 min after intravenous injection of AA-NPs. (Right column): In vivo imaging of 
mouse after intravenous injection (E) with and (F) without AA-NPs. (G) images of 
dissected organs of a mouse sacrificed 40 min after intravenous injection with AA-NPs. 1, 
kidney; 2, lung; 3, spleen; 4, liver; 5, heart; 6, bone; 7, stomach; 8, intestines; 9, muscle 
([117], reproduced by permission of Elsevier). 
 
One instance of multimodal imaging using MRI and PET was reported by Zhou et al. [117]. The 
authors prepared Na(Gd)YF4 nanoparticles co-doped with Er
3+
 and Yb
3+
. Incubation with KB cells for 
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even 1 h showed that the UCNPs penetrated the cells and bright upconversion luminescence was 
observed following 980 nm excitation. Strong contrast brightening was observed as the concentration 
of the Gd
3+
 ion increased in T1 weighted MR imaging. Pre and post in vivo MRI showed contrast 
enhancement in the spleen and liver after 15 min injection of the UCNP system. Preparation of 18F 
labeled UCNPs allowed for simultaneous MRI and PET imaging. Fifteen minutes post injection, 
intense radioactive signal were observed exclusively in the spleen and liver (similar to MRI contrast 
enhancement following the same time scale). The authors reported that low uptake of UCNPs was 
observed in the heart, lung and kidneys, which was similar to previous reports discussed above (Figure 19). 
Figure 19. Application of Fluorine labeled UCNPs as multimodal probes (A) 
Biodistribution of at different post-injection times; (B) Whole-body two-dimensional 
projection, and (C) transversal, (D) coronal, and (E) sagittal images of the liver (L) and 
spleen (S) of an in vivo injected mouse ([125], reproduced by permission of Elsevier). 
 
Imaging of the organs was reported by Cheng et al. [110] where 3 UCNP systems were prepared 
each one doped with a different Ln
3+
 ion with a specific upconversion emission signature (exc = 980 nm). 
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The authors were interested in multiplexed in vivo imaging of the lymphatic network in the neck and 
upper trunk of nude mice. Imaging of the mice pre and post-mortem showed that two lymph nodes 
could be identified using different upconversion emission wavelengths suggesting the high potential 
for using such a system for lymph node imaging. In addition the authors carried out in vivo cell 
tracking studies using KB cells. The authors incubated the cells with the UCNPs and following 
subcutaneous injection in mice and imaging, they were able to track the incubated cells. This was the 
first instance where color multiplex UCNP imaging was reported. The authors also demonstrated  
the imaging sensitivity of the UCNP system relative to QDs and showed that the detection power  
of UCNPs was one order of magnitude better than that of the QD systems due to the absence  
of autofluoresence. 
4.2. Imaging and Photodynamic Therapy 
UCNPs have been shown to be more than just bioprobes for upconversion fluorescence imaging of 
cancer. In fact, the notion of using upconverting sensitizers in PDT was discussed in the early  
1990’s [127–130]. Chatterjee et al. [118] demonstrated that folic acid (FA) conjugated NaYF4:Er
3+
, 
Yb
3+
 UCNPs could be used in photodynamic therapy (PDT) applications when in the vicinity of the 
photosensitive dye zinc phthalocyanine (ZnPC). In this paper, the authors physically adsorbed the 
ZnPC dye to the nanoparticle surface and tested its singlet oxygen production when in the presence of 
a molecular probe (ADPA, anthracene-9, 10-dipropionic acid), which is destroyed in the presence of 
the singlet oxygen species. This was accomplished by monitoring the absorption of ADPA at 400 nm 
following excitation with 980 nm NIR light and the results showed excellent effectiveness in 
generating singlet oxygen. Subsequently, the authors tested the FA-UCNP/ZnPC nanostructure in the 
presence of human colonic adenocarcinoma cells (HT29 cell line), which are known to overexpress 
folate receptors to determine their efficacy in photodynamic therapy. The authors showed that the cell 
viability decreased drastically when excited for 30 min at 980 nm. This was the first demonstration of 
the NIR excited UCNP being used in photodynamic therapy applications. 
Similarly Guo et al. [76] investigated the use of UCNPs with ZnPc for use in PDT therapy. The 
PDT drug was loaded in the pores of a mesoporous silica coating the UCNPs. The authors reported 
that significant singlet oxygen generation was obtained following irradiation with 980 nm exciting the 
UCNPs and energy transferring to the ZnPc (Figure 20). This was observed in MB49 PSA cells as well 
as in MTT assays where cell viability decreased significantly in ZnPc loaded UCNP systems relative to 
ZnPc alone. The secretion of PSA from MB49PSA allows the use of the former as a tumor marker. A 
30% decrease in PSA levels was measured in ZnPC-loaded UCNPs incubated cells due to the efficient 
cell death brought about by the UCNP system. 
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Figure 20. Detection of oxidative stress in live cells using MB49-PSA cells treated with 
NaYF4 nanoparticles (A–D) or ZnPc-loaded NaYF4 nanoparticles (E–H) followed by laser 
activation to induce oxidative stress. Insets in (A) and (E) show the region that has been 
enlarged in (B–D) and (F–H) respectively. Presence of reduced oxygen species are shown 
in green, (green) nuclei in blue, and the nanoparticles are shown by their red fluorescence 
color ([76], reproduced by permission of Elsevier). 
 
5. Luminescent UCNPs as Nanothermometers 
Up to this point, it was discussed that Ln
3+
-doped UCNPs are extremely useful for high-resolution 
fluorescence imaging of cancer. It has also been recently shown that fluorescent nanoprobes 
(nanocrystals, semiconductor QDs, nanogels, etc.) can be used for thermal sensing, i.e., for 
determining temperature gradients and temperature changes with a potential spatial resolution at the 
nanoscale and so at the cellular level [52,131–136]. These temperature sensitive fluorescent 
nanoprobes are now commonly referred to as ―fluorescent nanothermometers‖. The discovery of these 
nanothermometers could be of particular relevance for cancer therapy in order to control and 
understand the hyperthermia processes applied for the selective treatment of malignant cells [137–139]. 
Moreover, intracellular thermal measurements could be used as a non-invasive diagnostic tool by 
taking advantage of the temperature differences that seem to occur between healthy and pathological 
cells [140,141]. In this section we describe how UCNPs can be used for nanothermometry by invoking 
the particular case of the recently reported NaYF4:Yb
3+
,Er
3+
 upconverting nanothermometers [52]. 
The principle behind temperature measurement using a fluorophore (i.e., a fluorescent material) is 
rather simple. It is essentially based on the temperature sensitivity of one or more of the fluorophore 
emission features; such as emission intensity, shape, peak position or lifetime. Thus, knowing the 
temperature dependence of the spectral and/or temporal emission implies that the temperature of the 
investigated system can be determined. One of the main advantages of this method is its non-contact 
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nature, which provides minimal perturbation of the system under investigation. Indeed this advantage 
is essential for temperature measurements in fluids and particularly in biological systems. For these 
systems, multi-photon NIR-excited upconverting fluorophores are strongly preferred, so that 
autofluorescence (i.e., endogenous fluorescence of the system) and photo-bleaching (i.e., damage by 
ultraviolet-visible excitation light) are strongly reduced. In addition, the multi-photon excitation nature 
leads to an increased spatial resolution [23]. At present two types of nanoparticles have been reported 
to operate as two-photon excited fluorescent nanothermometers; CdSe and CdTe quantum dots [131], 
as well as NaYF4:Yb
3+
, Er
3+
 nanoparticles [52]. These nanoparticles produce visible luminescence 
under two-photon excitation and can be easily internalized by the cells [64] allowing for intracellular 
temperature measurements. Moreover, this approach allows also for cell imaging by means of  
two-photon excited fluorescence microscopy. Indeed these fluorescent nanoparticles or ―nanothermometers‖ 
provide the dual functionality of imaging and temperature sensing allowing for high spatial resolution 
intracellular thermal imaging. In fact, the actual resolution is limited by the Rayleigh limit in far-field 
fluorescence microscopes (200 nm) and could be even reduced in near field fluorescence microscopes 
(50 nm). These resolutions are considered high compared to the typical cell sizes of approximately 
tens of microns. 
Figure 21 shows the typical experimental arrangement for measuring intracellular temperatures by 
means of two-photon excited fluorescent nanoparticles. A NIR excitation tunable laser beam, tuned at 
the appropriate excitation wavelength, is focused onto the cell. The visible light emitted from the 
nanoparticles is directed to a spectrometer by means of a suitable dichroic mirror, which reflects only 
the visible fluorescence but not the NIR excitation light scattered by the cell. Thus, the temperature is 
determined in different points inside the cell by scanning the excitation beam across the cell while 
registering the emission spectrum given by the nanoparticles at each one of the selected points. It is 
important to mention that the NIR excitation laser wavelength must be selected to excite only the 
fluorescent nanoparticle while not interacting with the cell fluids. Otherwise, the cell can be heated by 
the excitation light, for instance by water absorption. Moreover, the input intensity must be low 
enough in order to minimize any light induced heating due to non-radiative de-excitations of the 
excited fluorescent nanoparticle, which could lead to undesired temperature alterations [142]. 
Figure 21. Typical experimental arrangement for measuring intracellular temperatures by 
means of two-photon excited fluorescent nanoparticles. 
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The ―nanothermometers‖ based on Ln3+-doped nanoparticles use two excited electronic energy 
states that, when de-exciting, produce two close emission bands, denoted by 1 and 2 in Figure 22. 
These exited states are so closely spaced that their populations, 1N  and 2N , are very sensitive to the 
environmental temperature by a well-known thermal equilibrium equation:  
kT
E
eC
N
N 

2
1
 
(1) 
where C is a constant for each particular ion-host system, E  is the energy gap between the two 
excited states, 
151062.8  KeVk  is the Boltzmann constant and T the absolute temperature. Thus, 
an increase in temperature produces a corresponding increase in the relative population N1/N2 and so in 
the relative emission intensity I1/I2 ≈ N1/N2 (where 1I and 2I are the intensities of the emissions labeled 
as 1 and 2 in Figure 22. As a result the temperature can be solved from equation (1) and so estimated if 
the emission intensity ratio I1/I2 is measured and E  and C are known. Usually the intensity I1/I2 ratio 
is previously calibrated as a function of temperature and a thermometric scale is obtained, so that a 
direct measure of the cell temperature is measured from the Ln
3+
-doped nanoparticle emission spectrum. 
Figure 22. Temperature estimation mechanism based on Ln
3+
 doped nanoparticles. 
 
At the present moment, nanothermometers based on NaYF4:Yb
3+
,Er
3+
 nanoparticles have been 
already reported [52]. In these nanothermometers, suitable excited states (labeled as 
2
H11/2 and 
2
S3/2) of 
Er
3+
 ions are used to produce two green emission bands centered at around 525 nm and 545 nm. The 
relative intensity of these emission bands I1/I2 = I525/I545 has been reported to be quite sensitive to 
temperature and so it has been used to measure absolute temperatures by means of a previously 
established calibration expression: 
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where T is given in K. In these nanothermometers Er
3+
 ion act as a temperature sensitive emitting ion 
while Yb
3+
 is used as an efficient NIR absorbing ion that populates the exited states of the emitting 
Er
3+
 ion via upconversion (Yb
3+
  Er3+ energy transfer). Thus a two-photon NIR excited green 
emitting NaYF4:Yb
3+
, Er
3+
 nanothermometer was developed, which was successfully used to image 
temperature gradients in liquids. More interestingly from the perspective of this work is that these 
nanoparticles were used for detecting intracellular temperature changes externally induced within 
HeLa cancer cells. In this case the cancer cells were heated by means of a metallic platform connected 
to a resistor in contact with the cell bath. By changing the applied voltage, the temperature was 
increased from about 25 °C to about 45 °C, where a small cell fragmentation started to be observed. 
Figure 23 demonstrates the ability of the NaYF4:Yb
3+
, Er
3+
 nanothermometers for measuring 
intracellular temperature changes within an individual HeLa cervical cancer cell. In this experiment, 
the cell was warmed by a laser beam at 980 nm (the heating beam) that illuminates the broad area 
marked in red. This beam is absorbed by the cellular fluid and produces a light induced heating. Then 
the temperature is measured within the heated area by exciting the Yb
3+
 ion (at the non-heating 920 nm 
wavelength) and recording the Er
3+
 green emission, and so the I1/I2 ratio, from which the temperature 
is determined. The right side in Figure 23 shows the intracellular temperature increase as a function of 
the heating beam power. By increasing the power of this beam up to 400 mW a temperature increase of 
about 14 °C is reached. This ―non-contact‖ heating is not relevant enough to produce morphological 
changes in the HeLa cell but manifests the ability of the NaYF4:Yb
3+
, Er
3+
 nanoparticles as 
intracellular nanothermometers within an accuracy of about 1 °C. Additional experiments are currently 
underway to improve the above-mentioned sensitivity by using other Ln
3+
 emitting ions. 
Figure 23. Intracellular temperature increase as a function of the heating beam power. 
 
6. Conclusions and Future Outlook 
Nanosystems have several important properties that distinguish them from other cancer therapeutic 
approaches since they can be designed and tailored for predetermined functionalities including: 
detection (through imaging), targeting (functionalization of one or more ligands), and therapeutics 
(nanoparticles or nanoparticle-drug conjugates). New synthetic methods have been developed to 
precisely control the size, shape and composition of the nanoparticles in order to tune absorption and 
emission properties for high contrast imaging agents [142]. In this respect, the novel upconverting 
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nanoparticles discussed herein present promising perspectives. As their absorption/emission properties 
are unaffected by size and shape and so by the inevitable size and shape dispersion, a typical problem 
associated to quantum and metallic nanoparticles. Moreover it does point to the dominant efficiency of 
the lanthanide doped nanoparticles with respect to these commercial nanoparticles, which opens new 
avenues for cheaper imaging technologies. The multimodal possibilities of the upconverting 
nanoparticles have been also here manifested and make them even more attractive not only as passive 
nanofluorophores but also as active nanofluorophores agents. 
In this respect, nowadays nanocarriers are being developed for drug delivery purposes and for 
increasing intracellular concentration of drugs in cancer cells, while minimizing toxicity in normal 
cells; simultaneously enhancing anti-cancer effects and reducing systemic toxicity [3,143]. Currently, 
two therapeutic nanocarrier-liposomes and albumin nanoparticle systems have already been approved 
by the USFDA for clinical practices [144]. In addition, nanoparticles can be used to target specific 
sites via surface modifications for providing specific biochemical interactions with the receptors of 
target cells as well as to deliver drugs to the target site, crossing several biological barriers. Some 
examples of these strategies have already been published by numerous research groups and has 
evaluated coating nanoparticles with polysorbates where the drug-loaded nanoparticles can be 
transported across the blood–brain barrier [145–147]; via coating with epithelial growth factor 
antibody-conjugated rapamycin-loaded nanoparticles showing an enhancing efficacy in MCF7 breast 
cancer-cell line [143], or finally by conjugating nanoparticles to a nuclear localization sequence for the 
direct targeting of doxorubicin to the nucleus of breast cancer cells [148]. Thus, the number of 
possibilities for the novel upconverting lanthanide nanoparticles, which we have shown to present an 
easy management of functionalization, is considerably increased. 
Apart from these possibilities, nanotechnology is also now being applied towards the development 
of relatively novel cancer therapies, including, gene therapy, photodynamic therapy (based in the 
combination of a photosensitizer, light and oxygen), radiotherapy and radiofrequency, as well as 
cancer theragnosis (combination of diagnosis and therapy) [149–152]. Thus, the development of  
upconverting nanoparticles as imaging contrast agents with a capacity for targeting tumours and also 
delivery of therapeutic agents together with the possibility of intracellular temperature determination 
provides a promising scenario for these multifunctional nanoparticles. In fact it does open the 
possibility of development of multifunctional nanoparticles to detect and kill cancer cells 
simultaneously and therefore, providing opportunities for designing properties that are not possible 
with other conventional types of therapeutic drugs. In essence we envisage bright future for these 
novel nanoparticles to support a new generation of cancer therapeutics. Nevertheless certain critical 
questions remain and must be addressed prior to the clinical development of any kind of nanoparticle 
for use in diagnostics and therapeutics in cancer (and other diseases). The current knowledge regarding 
the safety of nanoparticles is insufficient and speaks to the necessity for analysis of the 
pharmacokinetic behavior of different types of nanoparticles and the distribution and accumulation in 
tissue systems. This in itself, is not a trivial matter as many parameters will affect the toxicity and 
tissue localization of the nanoparticles including size, morphology, capping ligand(s), phase, 
crystallinity, and surface charge to name a few. 
In summary, the application of nanotechnology in cancer has experienced an exponential growth in 
the past few years. Nanoparticles provide opportunities for specific design and present fascinating 
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properties that are not possible with other drugs typically used in cancer therapies. Future studies will 
likely focus on active targeting with molecules for both specific recognition and cell internalization. 
Ultimately, this will lead to the development of a vehicle, which will be capable of targeting, imaging, 
diagnostics and therapeutics. Thus, there is no doubt that the development of these novel lanthanide 
doped nanoparticles will play a significant role in the near future. 
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